Steroids & PEDs

Testosterone enanthate is a long-acting ester of testosterone, the primary endogenous androgen in men. It is a licensed medicine for male hypogonadism and the most widely used compound in non-medical performance and physique contexts — both on its own and as the base of nearly every multi-compound protocol. Because it is bioidentical to endogenous testosterone once the ester cleaves, its effect profile is the reference point against which every other anabolic compound is described.

A long-acting testosterone ester near-identical in practice to enanthate, differing only in a marginally longer half-life. The most common TRT ester in the United States.

A very long-acting testosterone ester used clinically as a long-interval depot injection (Nebido/Aveed) and as an oral preparation. Once cleaved it is bioidentical testosterone; the exceptionally long undecanoate ester allows dosing every 10-14 weeks by injection.

Tamoxifen is a selective oestrogen receptor modulator (SERM) with decades of oncology trial data. It antagonises oestrogen at breast tissue (used to prevent and treat gynaecomastia) while acting as an oestrogen agonist at the hypothalamus/pituitary, raising LH, FSH and endogenous testosterone — which makes it a mainstay of post-cycle therapy (PCT).

A short-acting injectable ester of testosterone. Once the propionate ester is cleaved by serum esterases, the liberated hormone is bioidentical testosterone, so its effect and side-effect profile is that of testosterone itself. The short half-life means more frequent injections but faster clearance and easier titration.

Finasteride is a type II 5-alpha-reductase inhibitor that lowers dihydrotestosterone (DHT), used for male-pattern hair loss and benign prostatic hyperplasia. In the PED context it is used to reduce androgenic hair loss driven by DHT and DHT-derived compounds — but it does nothing against non-DHT androgens (e.g. nandrolone, trenbolone) and can worsen some, and it approximately halves PSA, which must be accounted for in prostate screening.

Isotretinoin is an oral retinoid (13-cis-retinoic acid) that produces durable remission of severe, treatment-resistant acne. In the PED context it is used for the severe androgen-driven acne that high-dose steroids can cause. It is highly effective but carries substantial risks: it is powerfully teratogenic, raises triglycerides and liver enzymes, dries skin and mucosa, and has a debated association with mood disturbance.

Letrozole is a highly potent non-steroidal (reversible) aromatase inhibitor. It is extremely effective at lowering oestrogen — so effective that it is the AI most likely to be over-used, crashing oestradiol to symptomatic levels. It has legitimate niche uses (established gynaecomastia reversal, ovulation induction) but for routine on-cycle oestrogen control it is easy to badly over-suppress.

A licensed blend of four testosterone esters (propionate, phenylpropionate, isocaproate and decanoate) totalling 250 mg/mL, designed to give both a fast onset and a sustained release from a single injection. Pharmacodynamically it is testosterone; the blend only shapes the release curve.

Un-esterified testosterone suspended in an aqueous vehicle. With no ester to cleave, it is pure testosterone that acts almost immediately and clears quickly, requiring daily (or more frequent) injection. The effect and side-effect profile is testosterone's, undiluted by ester weight.

A non-steroidal aromatase inhibitor used to control oestradiol on aromatising cycles. Effective and well studied — with over-suppression, not under-dosing, the more common error.

Cabergoline is a long-acting dopamine D2 receptor agonist used clinically for hyperprolactinaemia and Parkinson's disease. In the PED context it is used to lower prolactin elevated by 19-nortestosterone compounds (nandrolone, trenbolone), addressing prolactin-driven gynaecomastia and sexual dysfunction. Its long half-life allows twice-weekly dosing, but high cumulative doses carry a cardiac valve risk.

Steroidal, irreversible ('suicidal') aromatase inhibitor developed for post-menopausal breast cancer. In the PED context it is used to blunt oestrogen conversion from aromatising androgens. Because it is androgenic and does not raise SHBG the way non-steroidal AIs can, it is often favoured, but the recurring error is aggressive dosing that crashes oestradiol and produces joint pain, low libido and adverse lipids.

A medium-short injectable testosterone ester, best known as one of the four esters in Sustanon. Once cleaved it is bioidentical testosterone, so the effect and side-effect profile is testosterone's; the phenylpropionate ester sits between propionate and enanthate in duration.

Clomifene (clomiphene) is a SERM, a mixture of two isomers (enclomiphene and zuclomiphene). Like tamoxifen it blocks oestrogen feedback at the pituitary to raise LH, FSH and testosterone, and it is widely used in PCT and for male hypogonadism/fertility. Its distinctive drawback is oestrogenic-agonist visual side effects — blurring, floaters and flashes — driven largely by the long-lived zuclomiphene isomer.

Dutasteride is a dual (type I and type II) 5-alpha-reductase inhibitor, more complete and longer-acting than finasteride. It suppresses serum DHT by more than 90%, making it a stronger option for DHT-driven hair loss and BPH — with correspondingly greater potential for DHT-dependent sexual side effects and a very long half-life that means effects persist for weeks after stopping.

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that mimics luteinising hormone (LH), directly stimulating the Leydig cells of the testes to produce testosterone. It is used to maintain testicular size and function during suppressive cycles and as part of HPTA restart, preventing or reversing the testicular atrophy that exogenous androgens cause.

An orally active testosterone derivative bearing a 17-alpha-methyl group that resists hepatic breakdown. It delivers testosterone-like androgenic effects by mouth, but the 17-alpha-alkylation makes it distinctly hepatotoxic — the key difference from injectable esters, which are not.

Raloxifene is a second-generation SERM approved for osteoporosis and breast cancer risk reduction. In the PED context it is valued specifically for gynaecomastia: clinical data suggest it reduces established pubertal gynaecomastia more effectively than tamoxifen, making it a preferred SERM when glandular tissue has already formed.

A very short-acting injectable testosterone ester with a two-carbon acetate chain, even shorter than propionate. Once cleaved it is bioidentical testosterone; the tiny ester gives fast onset, quick clearance and a need for daily injection.

A medium-acting injectable testosterone ester, encountered chiefly as one of the four esters in Sustanon. Once cleaved it is bioidentical testosterone; the isocaproate ester gives an intermediate release rate between phenylpropionate and decanoate.

Pramipexole is a non-ergot dopamine D2/D3 receptor agonist used for Parkinson's disease and restless legs syndrome. In the PED context it is used, like cabergoline, to lower prolactin raised by 19-nortestosterone compounds. Being non-ergot it lacks the cardiac valve concern of cabergoline, but is dosed daily and is prone to nausea, somnolence and, notably, impulse-control problems.

A mild oral DHT-derived steroid with a genuine clinical history in burns and wasting. Popular for strength and definition without water retention — with a worse lipid profile than its gentle reputation suggests.

Enclomiphene is the trans-isomer of clomifene, isolated from the mixed drug to keep the potent oestrogen-antagonist activity while dropping the long-lived zuclomiphene isomer responsible for many of clomifene's side effects. It raises LH, FSH and testosterone in men with secondary hypogonadism and clears quickly, making it a cleaner SERM for raising testosterone while preserving fertility.

A long-acting ester of nandrolone (19-nortestosterone), the most-studied 19-nor anabolic. Added to testosterone protocols for lean mass and joint comfort, with a progestogenic side-effect profile and a very long detection window as the cost.

Fast-acting ester of nandrolone (19-nortestosterone), the same active steroid found in the better-studied decanoate. NPP delivers the classic nandrolone profile — strong lean-mass gains, joint-comfort and collagen effects, mild aromatisation and notable progestogenic activity — but with a short half-life allowing more frequent dosing and quicker clearance. Prized for its favourable anabolic-to-androgenic ratio relative to testosterone.

Oxymetholone ('Anadrol', 'A-bombs') is a potent 17α-methylated oral DHT-derived steroid used clinically for anaemia and wasting and recreationally for extreme mass and strength. It causes strong water retention and marked hepatic strain, and despite not aromatising it produces pronounced oestrogen-like effects through a poorly understood mechanism.

Stanozolol ('Winstrol', 'Winny') is a 17α-methylated DHT-derived steroid with a fused pyrazole ring, available orally and as an aqueous injectable. It does not aromatise and produces a dry, hardened look with strength gains rather than mass, making it a classic cutting and athletic-performance compound. It notably lowers HDL, strains the liver and is associated with joint discomfort.

Fluoxymesterone ('Halotestin', 'Halo') is a 17α-methylated, 9α-fluoro, 11β-hydroxy derivative of testosterone with very high androgenic potency and negligible mass-building effect. It is prized among strength and combat athletes for sharp increases in strength, aggression and hardness at low body-weight impact, but is strongly hepatotoxic and harsh on lipids.

Methandienone (methandrostenolone, 'Dianabol') is a 17α-methylated oral derivative of testosterone and one of the oldest and most widely used oral anabolic steroids. It produces rapid gains in mass and strength, driven substantially by water retention, and aromatises to a methylated oestrogen. Its speed made it a bodybuilding and strength-sport staple despite pronounced hepatic strain and oestrogenic side effects.

Stanolone is pharmaceutical dihydrotestosterone (DHT) itself, the most potent natural androgen, available medically as a transdermal gel or injection (androstanolone) for androgen deficiency. It is a strong androgen but weak systemic anabolic, cannot aromatise, and is used clinically where avoiding oestrogen conversion is desired. Its side-effect profile is androgenic — prostate, hair and skin — rather than oestrogenic.

An orally active DHT derivative (Proviron) used clinically for androgen deficiency and male infertility. It is weakly anabolic but a strong androgen-receptor binder and a modest anti-oestrogen, so it is used less to build muscle than to raise free testosterone by displacing it from SHBG, add a 'dry' hardening effect, and support libido. Not 17-alpha-alkylated, so low liver toxicity.

Chlorodehydromethyltestosterone ('Oral Turinabol', 'Tbol') is a 17α-methylated, 4-chloro derivative of methandienone. The chlorine at the 4 position blocks aromatisation, giving steady, oestrogen-free lean gains without water retention. It is infamous as the core agent of the East German state doping programme, and has an unusually long detection window from long-lived metabolites.

A four-ester testosterone blend of Polish/Jelfa origin, historically analogous to Sustanon. Original formulations combined testosterone propionate, phenylpropionate, and two longer esters; the modern reformulation mirrors Sustanon 250 exactly. Delivers the full testosterone effect profile with a staggered release from fast to slow esters.

Prasterone is the pharmaceutical name for dehydroepiandrosterone (DHEA), an endogenous adrenal prohormone available orally as a supplement and, in some regions, as a prescription product. Taken by mouth it is a weak androgen precursor that partly converts to testosterone and estrogens.

Oral testosterone ester (undecanoate) formulated in oleic acid to be absorbed via the intestinal lymphatics, bypassing first-pass hepatic metabolism. Marketed as Andriol/Restandol for testosterone replacement, it avoids the 17-alpha-alkylation hepatotoxicity of older oral androgens but delivers erratic, food-dependent, short-lived serum levels.

7-alpha-methyl-19-nortestosterone (MENT), an extremely potent 19-nor androgen originally developed as a male hormonal contraceptive and hormone-replacement candidate. It is many times more anabolic and androgenic than testosterone, cannot be 5-alpha reduced (staying active in prostate and skin), and aromatises to a potent oestrogen, producing rapid mass gains alongside a heavy oestrogenic and suppressive burden.

This entry covers the oral tablet formulation of oxymetholone, a potent 17-alpha-alkylated dihydrotestosterone derivative (2-hydroxymethylene modification) marketed as Anadrol-50. It is one of the strongest oral bulking steroids, clinically used for anaemia and HIV wasting, and is notable for rapid mass and strength gains alongside pronounced hepatic and estrogenic side effects.

This entry covers the oral tablet form of fluoxymesterone, a potent 9-fluoro, 11-beta-hydroxy, 17-alpha-methyl testosterone derivative marketed as Halotestin. It is one of the most androgenic oral steroids per milligram, clinically used for hypogonadism and inoperable breast cancer, and favoured non-medically for aggression and strength with minimal mass gain.

The most abundant circulating steroid in humans and a direct precursor to both androgens and estrogens. Sold widely as an over-the-counter supplement in the US, DHEA has genuine human trial data for age-related decline and adrenal insufficiency, but its performance and body-composition effects in healthy adults are weak to absent.

Dimethandrolone undecanoate (DMAU) is an orally active, long-chain ester of dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) under clinical development as a once-daily male hormonal contraceptive. It combines androgenic and progestogenic activity to suppress gonadotropins, is non-aromatising, and — unusually for an oral androgen — has been evaluated in modern controlled human trials with a comparatively favourable liver profile.

This entry covers the oral tablet form of mesterolone, a 1-methyl dihydrotestosterone derivative marketed as Proviron. It is an orally active, non-17-alkylated androgen used clinically for hypogonadism and low libido, and non-medically as an anti-estrogenic ancillary and free-testosterone booster rather than a mass-building steroid.

Ibutamoren (MK-677) is a non-peptide growth hormone secretagogue, not a SARM, that raises GH and IGF-1 by mimicking ghrelin. It is the most human-studied compound in this group, with trials in older adults, GH-deficient patients and others. Its hallmark effects are increased appetite, water retention and higher IGF-1; it does not suppress testosterone, so no steroid profile applies.

This entry covers the oral acetate tablet form of methenolone, a 1-methylated dihydrotestosterone derivative marketed as Primobolan. Unusually for an oral steroid it is not 17-alpha-alkylated, relying instead on 1-methylation for partial oral activity, which makes it comparatively mild on the liver but poorly bioavailable and expensive.

A mild, DHT-derived injectable (Primobolan) with a reputation as one of the 'safest' anabolic steroids. It is non-aromatising with a low androgenic burden, giving slow, lean gains with minimal oestrogenic or hepatic effects. It has genuine clinical history for anaemia and wasting, but its mildness means modest muscle-building relative to stronger compounds, and it remains fully suppressive.

A veterinary anabolic steroid (1-dehydrotestosterone) with a very long undecylenate ester, marketed for horses as Equipoise. Known for slow, lean, steady gains, marked appetite stimulation and a pronounced rise in red blood cell count. It aromatises at roughly half the rate of testosterone and is not progestogenic, giving a comparatively mild oestrogenic profile.

Mestanolone (17alpha-methyl-dihydrotestosterone) is an orally active, C17-alpha-alkylated derivative of DHT, marketed medically for decades as a mild androgen (e.g. Androstalone, Ermalone). It is strongly androgenic relative to its anabolic effect, does not aromatise, and confers a 'hard, dry' phenotype favoured pre-contest but is notable for pronounced neuro-androgenic stimulation and hepatotoxicity.

The oral form of methenolone (Primobolan tablets). Unusually among orals it is not 17-alpha-alkylated, so it is far less hepatotoxic than typical oral steroids, but this also gives it poor oral bioavailability, requiring relatively large daily doses. It shares methenolone's mild, non-aromatising, DHT-derived profile: gentle lean gains with a low side-effect burden.

A long-chain (10-carbon) ester of testosterone best known as one of the four components of Sustanon. As a standalone raw ester it is uncommon, but its slow release makes it a component of choice in blends and some long-acting testosterone preparations. Effects are identical to any testosterone preparation once the ester is cleaved; the decanoate chain simply stretches the release window.

Calusterone (7beta,17alpha-dimethyltestosterone) is an orally active 17-alpha-methylated androgen that was investigated as an antineoplastic agent for advanced breast cancer in the 1970s under the brand Methosarb. It is a moderately anabolic, weakly aromatising oral with documented human clinical exposure in oncology, alongside the hepatotoxicity typical of methylated orals.

A DHT-derived, non-aromatising injectable (2-alpha-methyl-dihydrotestosterone) historically used to treat breast cancer for its anti-oestrogenic effect. In bodybuilding it is valued for a hard, dry, defined look near contest time rather than raw mass, with a short propionate ester requiring frequent injection. Androgenic side effects (hair loss, acne) predominate; oestrogenic effects are essentially absent.

Methasterone ('Superdrol') is a 17α-methylated DHT-derived steroid (2α,17α-dimethyl) that emerged as a 'prohormone'/designer steroid sold over the counter in the 2000s before being scheduled. It delivers rapid, dry strength and lean mass, but is notably hepatotoxic with multiple documented cases of severe cholestatic liver injury even at label doses.

A very long-acting ester of nandrolone marketed in Europe as Anadur (Anadurine), used clinically for anaemia, osteoporosis and cachexia with dosing intervals of up to several weeks. It delivers the well-characterised nandrolone profile — lean mass, collagen and erythropoietic effects with progestogenic sexual side effects — with an unusually slow release even relative to the decanoate.

Ostarine (enobosarm, MK-2866) is a non-steroidal selective androgen receptor modulator investigated for muscle wasting and cachexia. It is the most clinically studied SARM, having reached Phase II/III trials, yet it remains unapproved for any indication and is banned in sport. Anecdotal recreational use targets lean-mass gains at low doses, with testosterone suppression and lipid changes as the main documented downsides.

An ultra-long-acting testosterone ester (trans-4-n-butylcyclohexane carboxylate) developed as a candidate depot for hormonal male contraception and hypogonadism, with a single injection sustaining levels for many weeks. Its effects are those of testosterone; it was studied in small human trials but never widely marketed.

Testosterone propionate is the androgenic component of steer-specific cattle growth implants such as Synovex-S and Revalor-S, usually paired with estradiol benzoate. In the implant it drives weight gain in feedlot steers; the same short-ester testosterone is also the classic diverted androgen for human PED use.

Trenbolone attached to a hexahydrobenzylcarbonate ester, the only trenbolone form ever sold as a human pharmaceutical (Parabolan, France) before withdrawal. Pharmacologically it is trenbolone — extremely potent, non-aromatising, strongly progestogenic — with a long-acting ester. It shares the same severe side-effect burden and the same thin, mostly veterinary/anecdotal evidence base.

A generic multi-ester testosterone blend modelled on the Sustanon concept, combining short, medium and long esters (typically propionate, phenylpropionate, isocaproate and decanoate) in one oil solution. The staggered esters give a fast onset from the short fractions and a sustained tail from the long ones, allowing less frequent dosing than a single short ester. Widely counterfeited, so exact ratios vary between products.

A moderately long-acting nandrolone ester using the cypionate (cyclopentylpropionate) chain, giving release kinetics similar to nandrolone decanoate. Effects match nandrolone (deca); it is less commonly manufactured than decanoate or phenylpropionate, so ester-specific human data are thin.

Oxymesterone (4-hydroxy-17α-methyltestosterone) is a 17α-methylated oral androgen once marketed as a pharmaceutical (Oranabol) in some countries. It has a moderate, relatively balanced anabolic-androgenic profile with weak oestrogenic activity, and like other 17α-alkylated orals carries meaningful hepatotoxicity. It is little-used today and has thin modern human data.

Winstrol-V is the veterinary formulation of stanozolol, a DHT-derived anabolic marketed for horses and dogs to improve appetite, condition and recovery. Both the injectable aqueous suspension and oral forms have been heavily diverted to human PED use, giving stanozolol its long-standing 'cutting' reputation.

A long-ester form of trenbolone, an extremely potent 19-nor androgen that does not aromatise but is strongly progestogenic. It produces dramatic strength and recomposition effects but carries the heaviest side-effect burden of common anabolic steroids — night sweats, insomnia, aggression, cardiovascular strain and 'tren cough'. Almost all data are veterinary or anecdotal; no human trials exist.

4-chlorotestosterone, a testosterone derivative whose 4-chloro substitution blocks aromatisation and 5-alpha reduction, yielding a mild, non-estrogenic anabolic. Best known today via its acetate ester in topical wound-healing creams (Trofodermin), which have caused several high-profile inadvertent doping positives.

The long-ester version of drostanolone (Masteron), pharmacologically identical to the propionate but with a slower release allowing less frequent injection. It shares the same DHT-derived, non-aromatising, dry-hardening profile and the same androgenic side-effect pattern; only the ester and dosing frequency differ. Human clinical data are limited to the older propionate breast-cancer use.

Ligandrol (LGD-4033) is a non-steroidal SARM with higher potency than ostarine, studied in small Phase I trials for safety and lean-mass effects. It is popular in anecdotal recreational use for strength and size but reliably suppresses testosterone even at low milligram doses. It is unapproved, prohibited in sport, and linked to case reports of liver injury.

Methyl-1-testosterone (M1T) is a 17α-methylated derivative of 1-testosterone (dihydroboldenone) that was sold as a 'prohormone' in the mid-2000s. It is extremely potent by milligram, giving fast dry mass and strength, but is correspondingly harsh: strongly hepatotoxic, heavily suppressive and often accompanied by lethargy and malaise.

Methyltrienolone ('Metribolone', 'oral tren', R1881) is a 17α-methylated derivative of trenbolone and one of the most potent androgens known. Its extreme AR affinity and non-aromatising, non-5AR-reduced profile make it a benchmark androgen in laboratory research, but as a human drug it is regarded as extraordinarily hepatotoxic and toxic overall, used only at microgram doses if at all.

Mibolerone ('Cheque Drops') is a 17α-methylated 19-nortestosterone (nandrolone) derivative originally a veterinary drug used to prevent oestrus in dogs. It is extraordinarily potent and androgenic, used by some strength and combat athletes for a very short-lived surge of aggression before competition. It is progestogenic, strongly hepatotoxic and considered one of the harshest steroids in use.

A very long-acting (12-carbon laurate) ester of nandrolone, marketed for veterinary use as Laurabolin. Effects mirror nandrolone (deca) but the long ester gives an extended, flat release requiring infrequent injection. Human data are limited; most evidence is veterinary and anecdotal.

A long-acting nandrolone ester using the 11-carbon undecanoate chain, giving a slow, extended release similar to (or slightly beyond) decanoate. Effects match nandrolone; it is an uncommon preparation with limited ester-specific human data.

The injectable microcrystalline aqueous suspension form of stanozolol, the DHT-derived oral/injectable steroid sold pharmaceutically as Winstrol Depot. Because stanozolol is not esterified, the aqueous suspension releases the same molecule found in the tablets, only via a slow-dissolving crystal depot. It is prized for lean, dry mass gains without aromatisation but retains oral-type 17-alpha-alkyl hepatotoxicity even by injection.

A medium-length hexanoate ester of testosterone, historically a component of some combination testosterone injectables and depot preparations. Pharmacologically it is bioidentical testosterone with a release rate between propionate and enanthate. It is uncommon as a standalone product and is best known as one of the esters blended into legacy multi-ester testosterone mixtures.

A potent 19-nor androgen originally developed for cattle, never approved for human use. Produces dramatic recomposition alongside the heaviest side-effect burden of any compound in common use.

The veterinary trenbolone acetate implant (Finaplix, Component TE) is the cattle growth-promotant form of trenbolone acetate, marketed as compressed subcutaneous ear pellets. Diversion of these pellets to make injectable trenbolone for human use is the classic route by which a cattle drug entered bodybuilding.

The veterinary Equipoise product is boldenone undecylenate formulated for horses, and it is the single most-diverted veterinary anabolic in bodybuilding. Approved to improve appetite, weight and coat in debilitated horses, its long-ester boldenone gives slow, steady lean gains that made it a staple of illicit human cycles.

The short-ester injectable form of methenolone (Primobolan), using the propionate chain for a fast, short release requiring frequent injection. Effects mirror methenolone: mild, non-aromatising, DHT-derived anabolic favoured for lean gains and cutting, with low androgenicity and no estrogenic activity.

One of the earliest commercial oral anabolic steroids, marketed as Nilevar from the mid-1950s. A 17-alpha-ethylated 19-nortestosterone derivative, it was used for wasting and osteoporosis but developed a reputation for pronounced hepatotoxicity, virilisation and progestogenic side effects, and was largely superseded by cleaner agents.

An oil- or water-based injectable preparation of oxymetholone (Anadrol), a powerful 17-alpha-alkylated DHT-derived oral steroid. Injecting the unesterified molecule aims to reduce the digestive burden of high oral tablet doses, but because oxymetholone retains its 17-alpha-alkyl group it remains hepatotoxic by injection. It produces dramatic mass and strength gains alongside significant water retention and side effects.

Trenbolone hexahydrobenzylcarbonate is the long-ester veterinary/human-grey form of trenbolone (Parabolan, originally Finajet/Hexabolan lineage), releasing the same potent 19-nor trienolone androgen slowly over weeks. It is among the most sought-after diverted trenbolone esters, with a powerful anabolic effect and a harsh side-effect profile.

The acetate ester of clostebol (4-chlorotestosterone), a mild anabolic steroid used in some countries in injectable and topical medicinal preparations, including wound-healing ointments. The 4-chloro substitution blocks aromatisation and 5-alpha reduction, giving a mild, non-oestrogenic profile. It is best known in anti-doping circles for causing positive tests via contaminated topical products.

A long-acting trenbolone ester (cyclohexylmethylcarbonate), historically the active ingredient in the veterinary product Parabolan. Effects mirror trenbolone: powerful, non-aromatising anabolism with strong androgenic and progestogenic activity and pronounced side effects. Human data are limited and largely anecdotal.

A weakly androgenic oral 19-nortestosterone derivative that lacks the 3-keto group, marketed under names such as Maxibolin and Orabolin for wasting and as a veterinary agent. It is essentially a prodrug-like relative of norethandrolone and is considered mild but hepatotoxic due to 17-alpha-alkylation.

An injectable oil solution of methenolone acetate, the short-acting acetate ester of primobolan's parent DHT-derived steroid. Acetate esterification of methenolone is more commonly encountered orally, but an injectable oil form gives fast onset with frequent dosing. It shares primobolan's reputation as a mild, non-aromatising, well-tolerated cutting steroid with a favourable side-effect profile at the cost of modest potency.

Nandrolone laurate (Laurabolin) is a very long-ester veterinary form of nandrolone used in horses, dogs and cattle to improve appetite, condition and recovery. Its slow-release laurate ester gives prolonged nandrolone exposure from infrequent injections, and it has been diverted to human PED use.

A testosterone precursor that converts to testosterone in one enzymatic step, popular in the late-1990s/early-2000s prohormone era. It raises testosterone but a large fraction also aromatises to estrogen. Now a DASCA-scheduled controlled substance in the US.

A short-ester version of boldenone, the anabolic behind Equipoise (EQ). The propionate chain gives a fast, short release requiring frequent injection, unlike the long-acting undecylenate. Effects mirror boldenone: steady lean gains, appetite and red-cell stimulation with modest estrogenic activity. Ester-specific data are minimal.

A very short-acting acetate ester of drostanolone (Masteron), requiring daily or every-other-day injection. Effects mirror drostanolone: a mild, non-aromatising DHT-derived anabolic with mild anti-estrogenic activity, favoured for hardening and cutting. Ester-specific human data are minimal.

Estradiol benzoate is the estrogenic component of many combination cattle growth-promotant implants (e.g. Synovex, Revalor), usually paired with an androgen such as testosterone propionate or trenbolone acetate. It drives weight gain in cattle through the GH/IGF-1 axis and has no androgenic PED value in humans.

The enanthate ester of 7α-methyl-19-nortestosterone (MENT/trestolone), a long-acting injectable form of the Population Council's male-contraceptive androgen. About 10x more potent than testosterone, prostate-sparing, but strongly suppressive and progestogenic. The acetate is separately catalogued; this is the longer ester used off-label.

Mepitiostane is an orally active anabolic steroid and antiestrogen derived from epitiostanol (a thioether DHT derivative), used in Japan under the brand Thioderon for breast cancer and to raise erythropoietin production. It is a prodrug of epitiostanol and behaves as both a mild androgen and an estrogen-receptor antagonist.

Methylnortestosterone (17alpha-methyl-19-nortestosterone, MENT's oral relative) is an orally active 19-nor androgen investigated in the context of male hormonal contraception via its acetate/enanthate injectable cousins. The 17-alpha-methylated oral form is a potent, non-aromatising (weakly aromatising) androgen with progestogenic activity, oral hepatotoxicity, and strong gonadotropin suppression.

A nandrolone precursor that converts to nandrolone (19-nortestosterone) rather than testosterone. Famous for triggering nandrolone-positive doping tests in athletes who took over-the-counter supplements in the late 1990s. Now a DASCA-scheduled controlled substance.

Androstenedione (4-Andro) is a naturally occurring steroid hormone and direct precursor to testosterone, marketed as a testosterone-boosting prohormone. Despite early clinical study, oral supplementation raises estradiol at least as much as testosterone and confers little anabolic benefit — it was banned as a supplement in the US in 2004.

A weak endogenous androgen and DHT metabolite that also serves as a prohormone, back-converting in part to DHT and downstream androgens. Sold as a 'hardening' prohormone for a dry, aggressive look. Non-aromatising and DASCA-scheduled in the US.

A very short-acting acetate ester of boldenone, requiring near-daily injection. Effects mirror boldenone (Equipoise): gradual quality lean gains, appetite and red-cell stimulation, moderate estrogenic activity. Ester-specific human data are essentially absent.

A shorter-ester alternative to the familiar boldenone undecylenate (Equipoise), pairing the same 1-dehydrotestosterone steroid with a cyclopentylpropionate ester. It offers the boldenone profile — slow lean gains, appetite stimulation and pronounced erythropoiesis with modest aromatisation and no progestogenic activity — but with faster clearance than the undecylenate. Human data are minimal; it exists almost entirely as an underground product.

Cardarine (GW-501516) is not a SARM but a PPARδ agonist, developed for dyslipidaemia and studied for its effects on fat metabolism and endurance. Development was halted after long-term rodent studies showed dose-dependent cancers in multiple organs. This carcinogenicity signal is the dominant safety concern; whether it translates to humans is disputed and unresolved.

1-testosterone (5-alpha-dihydroboldenone), a non-aromatising androgen usually sold as the cypionate ester. It combines a strong anabolic effect with a lean, 'dry' physique and is not oestrogenic, but is notorious for severe post-injection pain and lethargy. Human data are minimal, so its profile is drawn largely from anecdote and structural analogy.

A Japanese DHT-derived oral steroid (Miotolan) bearing a furazan (oxadiazole) ring fused to the A-ring, structurally akin to stanozolol. Studied and used partly for its reputed cholesterol-lowering effect, it is a non-aromatising, 17-alpha-methylated oral with the usual hepatic and lipid liabilities.

GSK2881078 is a non-steroidal SARM developed by GlaxoSmithKline that reached early-phase human trials for muscle wasting and sarcopenia, including studies in older adults and patients with COPD. It produced modest measurable increases in lean mass and is one of the better-characterised experimental SARMs, though still far from approval.

An injectable preparation of fluoxymesterone (Halotestin), a fluorinated 17-alpha-alkylated testosterone derivative normally taken orally. It is one of the most androgenic-per-milligram steroids, prized by strength and combat athletes for aggression and strength without weight gain. Injecting the unesterified molecule does not lessen its notorious hepatotoxicity, and it remains a harsh, poorly characterised compound in injectable form.

Mibolerone (Cheque Drops) is an extremely potent orally active 19-nortestosterone androgen originally marketed as an oral liquid to prevent estrus in female dogs. Diverted to bodybuilding, it is used in tiny microgram doses as a short-acting pre-competition aggression booster, with a harsh side-effect profile and no human approval.

Mibolerone (7alpha,17alpha-dimethyl-19-nortestosterone) is an extremely potent orally active 19-nor androgen originally licensed in veterinary medicine (Cheque Drops) to suppress estrus in dogs. In humans it is used non-medically in tiny sublingual/oral doses shortly before competition or heavy training for a short-lived surge in aggression; it is highly androgenic, progestogenic, hepatotoxic and dangerous at above micro-doses.

Oxendolone is a steroidal antiandrogen and weak anabolic-androgenic steroid (16-beta-ethyl-19-nortestosterone) developed in Japan as TSAA-291 and marketed as Prostetin for benign prostatic hyperplasia. It combines weak androgenic activity with antiandrogen and progestogenic properties.

Penmesterol (methyltestosterone 3-cyclopentyl enol ether) is an orally/parenterally used androgen ester-ether prodrug of methyltestosterone, marketed historically in some European markets. As a methyltestosterone derivative it is aromatisable, moderately androgenic, and shares the hepatotoxicity of 17-alpha-methylated orals; documented human medical use is limited and dated.

Testolone (RAD-140) is a potent non-steroidal SARM originally explored for breast cancer and muscle wasting. Human data are minimal, limited largely to an early oncology trial, so most claims are preclinical or anecdotal. Recreational users report strong strength and size gains alongside marked testosterone suppression, and case reports link it to liver injury.

An obscure testosterone ester formed with nicotinic acid (niacin). Historically appearing in a handful of mid-20th-century preparations, it is essentially absent from modern medicine and sport. Its effects are those of testosterone; ester-specific human data are extremely sparse, so it is characterised largely by inference from the parent hormone.

An unusual and rarely encountered presentation of testosterone undecanoate as a fine aqueous microcrystalline suspension rather than the standard castor-oil depot. The undecanoate ester and poor water solubility make a true aqueous suspension impractical, so most products sold under this description are either mislabelled oil solutions or crude micronised preparations with erratic release. Where genuine, it behaves as a long ester with slow, unpredictable absorption from the injection depot.

Zeranol (Ralgro) is a non-steroidal resorcylic acid lactone growth promotant derived from the fungal mycotoxin zearalenone. It is a potent, orally and subcutaneously active estrogen agonist implanted in beef cattle and sheep to increase weight gain and feed efficiency. It has no legitimate human use and is banned as a growth promotant in the EU.

1-Androsterone (1-DHEA) is a non-methylated prohormone that converts to 1-testosterone (dihydroboldenone), a non-aromatising DHT-like androgen. Popular in legal-until-2014 supplements, it produces dry lean gains anecdotally but suppresses natural testosterone and can lower HDL; human data is limited to case reports and one small pharmacokinetic study.

A DHEA-adjacent diol with the double bond in the 5-position, requiring two enzymatic steps to reach testosterone and therefore a weaker testosterone precursor than 4-androstenediol. Notable separately for radioprotective/immune research. A DASCA-scheduled controlled substance in the US.

Boldione (androsta-1,4-diene-3,17-dione) is the direct prohormone of boldenone (Equipoise). It is a weak androgen in its own right that converts in vivo to boldenone, and was widely sold as an oral 'prohormone' supplement before being scheduled as an anabolic steroid in the US in 2005.

17-alpha-methylandrostenediol, a mild anabolic that is a methylated derivative of the testosterone precursor androstenediol. Sold historically for human use and still found in veterinary products, often as the dipropionate ester, it is regarded as weak but with a reputation for synergising other steroids.

Methylandrostenediol (17-alpha-methyl-5-androstene-3-beta,17-beta-diol) is an orally active anabolic steroid and a testosterone prohormone, historically studied as an anabolic agent and later sold as a 'prohormone' supplement. It is the 17-alpha-methylated analogue of androstenediol.

Methyltrienolone (metribolone, R1881; 17alpha-methyl-trenbolone) is an extraordinarily potent orally active 19-nor androgen used mainly as a laboratory radioligand for the androgen receptor. Its non-medical use is limited to tiny doses because of extreme hepatotoxicity; it has one of the highest anabolic/androgenic ratings on record but is regarded as one of the most liver-toxic AAS known.

A popular post-2014-scheduling-era prohormone that converts to 1-androsterone and ultimately 1-testosterone, a non-aromatising DHT-derived androgen. Prized in the community for 'dry' lean gains without estrogen conversion, but suppressive and unstudied in humans. DASCA-scheduled in the US.

A 4-ene DHEA analog that converts through androstenedione/androstenediol to testosterone, marketed as a mild 'bulking' prohormone that mimics low-dose testosterone. Aromatises, so estrogen management matters. DASCA-scheduled in the US.

The cypionate ester of dihydroboldenone (1-testosterone), a potent DHT-class injectable often marketed as '1-Test Cyp' or DHB. It is essentially the 5-alpha reduced form of boldenone and cannot aromatise, giving strong, dry strength and mass gains without estrogenic bloat. It is notorious for painful injections and pronounced lethargy, and has little formal human characterisation.

Hydroxymesterone (typically the 11-beta-hydroxy analogue of methyltestosterone, closely related to fluoxymesterone without the 9-fluoro) is a 17-alpha-methylated oral androgen. It is strongly androgenic with limited aromatisation, and shares the hepatotoxicity and suppression of the fluoxymesterone family. Human data are sparse and largely historical.

PF-06260414 is a non-steroidal selective androgen receptor modulator developed by Pfizer that reached a single-dose Phase 1 study in healthy men. It is one of the few SARMs with any published human pharmacokinetic and safety data, though characterisation remains early and limited to short exposure.

Thiomesterone (tiomesterone) is an orally active anabolic-androgenic steroid, a 1,7-bis(acetylthio) derivative of methyltestosterone, marketed historically in Europe as Emdabol. It behaves as a 17-alpha-methylated oral androgen with the two acetylthio groups distinguishing it from the parent compound.

The diol form of the 1-testosterone pathway, converting to 1-testosterone (dihydroboldenone) via one fewer oxidation step than 1-DHEA. A non-aromatising, dry-gain prohormone with the same DHT-type side effect and suppression profile. DASCA-scheduled in the US.

An injectable cypionate ester of 1-testosterone (dihydroboldenone, DHB), a highly anabolic non-aromatising steroid structurally related to boldenone but 5-alpha reduced. It is valued for lean, dry gains and a strong anabolic-to-androgenic ratio, but is notorious for severe, prolonged post-injection pain that limits its practical use. Human evidence is essentially anecdotal.

Andarine (S-4) is an early non-steroidal SARM studied mainly in animals for muscle and bone. Human evidence is essentially absent, so claims rest on preclinical work and anecdote. It is notable for a distinctive, reversible visual side effect (yellow tinting and night-vision problems) at higher doses, alongside the usual testosterone suppression.

Epiandrosterone (3β-hydroxy-5α-androstan-17-one) is a naturally occurring DHEA metabolite and non-methylated prohormone to dihydrotestosterone (DHT). Marketed for 'dry, hard' physique effects, it is one of the milder prohormones with low hepatotoxicity, but efficacy rests almost entirely on anecdote.

Melengestrol acetate (MGA) is a highly potent orally active progestin fed to feedlot heifers to suppress estrus and improve weight gain and feed efficiency. It is a growth-promoting progestational agent with no human therapeutic use; its relevance here is as a feed-additive growth promotant and a residue/detection concern.

An injectable diester of methandriol (17-alpha-methylandrostenediol), a weakly anabolic steroid historically used both on its own and as an adjunct thought to potentiate other steroids. The dipropionate ester provides a depot release. It is mild, dated and lightly studied, better known as a vintage veterinary and combination product than as a standalone mass-builder.

An orally active cyclopentenyl enol ether of boldenone, marketed in Italy as Anabolicum Vister. It is essentially an oral prodrug of boldenone (Dianabol's non-methylated relative) and was used for geriatric and paediatric anabolic therapy, but it is weakly effective orally and has largely vanished.

The 'Clear' at the centre of the BALCO doping scandal — a non-esterified oral progestin-derived steroid engineered to be undetectable until anti-doping chemists reverse-engineered it in 2003. Potent androgen and progesterone receptor activity in vitro, but no legitimate human trials.

19-Nor-DHEA (19-nor-androst-4-ene-3β-ol,17-one) is a non-methylated prohormone that converts to nandrolone (19-nortestosterone). Marketed for lean-mass gains, it carries nandrolone's progestogenic risk profile — potential libido loss and mood effects — with efficacy resting entirely on anecdote.

Altrenogest (Regu-Mate) is a potent orally active progestin used to control the estrous cycle in mares and to synchronise breeding in swine. It is a 19-nortestosterone-derived progestogen with no anabolic bodybuilding role; it appears in doping and residue contexts and is hazardous through skin contact for handlers.

Androisoxazole is an orally active anabolic-androgenic steroid derived from dihydrotestosterone in which an isoxazole ring is fused to the A-ring, structurally analogous to danazol and to the isoxazole-fused compound azolol. It saw limited use in Europe under the brand Neo-Ponden but was never widely studied, so human data are sparse.

Formyldienolone, a methandienone-derived steroid marketed in Italy and Spain (Esiclene, Hubernol). Injected locally by bodybuilders to create short-term muscle swelling for stage cosmetics rather than for real mass, because it induces local inflammation.

Methandriol diacetate is the 3,17-diacetate ester of methandriol (17-alpha-methylandrostenediol), an oral/injectable anabolic-androgenic steroid used historically as a veterinary and human anabolic. The diacetate ester alters solubility and duration relative to the parent methandriol and its dipropionate ester.

Methylepitiostanol ('Epistane', 2,3-epithio-17alpha-methyl-5alpha-androstan-17beta-ol) is a 17-alpha-methylated epithio (2,3-epithio) DHT-derived designer steroid that also has anti-estrogenic activity. It provides dry lean gains and mild aromatase/estrogen-antagonist effects, with the hepatotoxicity and suppression typical of methylated orals and only anecdotal human data.

An injectable oil suspension of methasterone (methyldrostanolone, 'Superdrol'), a highly potent 17-alpha-alkylated DHT-derived steroid usually taken orally. Injecting the unesterified compound does not remove its 17-alpha-alkyl group, so it remains strongly hepatotoxic while delivering large, dry strength and mass gains. It is a harsh compound with minimal formal human study, favoured for short, aggressive cycles.

Epistane (methylepitiostanol) is a 17α-methylated designer steroid derived from epitiostanol, with anti-estrogenic and 'dry, hard' effects. Widely used as a lean-gain/recomp prohormone, it is hepatotoxic and suppressive, and has been linked to cholestatic liver injury case reports.

Norgestomet is a potent synthetic progestin delivered by subcutaneous ear implant (Crestar/Syncro-Mate-B) to synchronise estrus in cattle, often combined with estradiol. It is a 19-nortestosterone-derived progestagen used for reproductive management and growth-linked programmes, with no anabolic PED value.

An 11-oxygenated DHEA analog positioned as a precursor to 11-keto androgens (the 11-oxyandrogen pathway now recognised as clinically relevant). Marketed as a mild recomposition prohormone with limited human data and an uncertain regulatory footing.

A potent 7-alpha,17-alpha-dimethyl testosterone derivative developed in the 1960s (Myagen). It is strongly anabolic and androgenic and orally active, but was withdrawn early and is essentially uncharacterised in the modern literature, surviving mainly as a doping-control reference and grey-market curiosity.

Bolenol is an orally active anabolic-androgenic steroid, a 19-nortestosterone (estrene) derivative bearing a 17-alpha-ethyl group and lacking the 3-keto function. It is closely related to ethylestrenol and was described in older pharmacological literature as a weakly androgenic oral anabolic agent.

A synthetic oral androgen ('Madol', DMT) with no ester and no 3-keto group, identified by anti-doping labs in 2005 after being distributed as a designer steroid intended to evade detection. Preclinical assays suggested strong anabolic activity, but essentially no controlled human data exist.

Halodrol (4-chloro-17α-methyl-androst-1,4-diene-3β,17β-diol) is a 17α-methylated designer steroid structurally related to turinabol. Sold as a 'prohormone' but effectively an oral anabolic steroid, it produces lean gains anecdotally at the cost of notable hepatotoxicity and HPTA suppression.

Mebolazine (dimethazine's chemical cousin; the azine dimer of mestanolone, also called dymethazine in some literature) is an orally active designer steroid formed by joining two mestanolone-like units via a nitrogen-nitrogen azine bridge that hydrolyses in vivo to release active 17-alpha-methyl-DHT. It is a non-aromatising, dry, strongly androgenic and hepatotoxic oral with essentially no controlled human data.

Methylboldenone (17-alpha-methylboldenone) is an orally active, C17-alpha-alkylated derivative of boldenone. It combines boldenone's diene structure with a methyl group for oral bioavailability, producing a hepatotoxic oral anabolic that surfaced in the grey-market designer/prohormone scene. Human study is essentially absent.

A long-acting decanoate ester of 7-alpha-methyl-19-nortestosterone (MENT), a potent synthetic androgen that resists both aromatisation to a normal estrogen pattern and 5-alpha reduction. The parent MENT was investigated as a male contraceptive and androgen replacement agent; the decanoate ester extends its duration for depot delivery. It is a research-grade compound with very limited human characterisation in this esterified form.

An obscure injectable 19-nortestosterone derivative (4-hydroxynandrolone cipionate) once marketed in Europe under names such as Steranabol. It is a metabolite-like relative of nandrolone with mild anabolic activity and low androgenicity, of interest mainly historically and to anti-doping laboratories. Human performance data are essentially nonexistent.

A non-aromatising DHT-derived injectable anabolic (2-methyl-1-dehydro-DHT), closely related to methenolone (Primobolan). Marketed briefly as the acetate (Anatrofin/Stenbolone), it is a mild, dry, non-estrogenic compound that never gained a foothold and is essentially uncharacterised in modern studies.

A long-acting testosterone ester using the hexahydrobenzylcarbonate (cyclohexylmethyl carbonate) group, the same carbonate ester used in the veterinary trenbolone product Parabolan. Applied to testosterone it would give a slow, extended depot release comparable to enanthate or slightly longer, allowing infrequent dosing. It has no pharmaceutical history and is essentially a theoretical/underground testosterone ester.

A long-acting decanoate ester of trenbolone, a potent non-aromatising 19-nor androgen. Trenbolone is normally esterified as acetate (short), enanthate (medium) or hexahydrobenzylcarbonate (long); a decanoate ester would give one of the longest release profiles, allowing infrequent injection of this powerful compound. It has no pharmaceutical history and is an underground extension of the trenbolone-ester family.

Penmesterol is an orally active anabolic-androgenic steroid, a 17-alpha-methyltestosterone derivative bearing a 3-cyclopentyl enol ether, described in older European pharmacological literature. It behaves as a long-acting methyltestosterone-type oral androgen and is of largely historical interest.

ACP-105 is a non-steroidal SARM characterised only in preclinical studies, including work on muscle, bone and cognition in animals. There is no human data, so all claims are preclinical or anecdotal. It is expected to share the SARM class profile of testosterone suppression and lipid changes and is unapproved and prohibited in sport.

Androstanazole is a pyrazole-fused dihydrotestosterone derivative belonging to the same heterocyclic-steroid family as stanozolol, described in older medicinal-chemistry literature as an orally active anabolic candidate. Human data are essentially absent and it is of historical/chemical interest.

Chlorodehydromethylandrostenediol (CDMA, marketed as 'Halodrol' prohormone versions and 'Promagnon') is the 3-beta-hydroxy diol precursor to 4-chlorodehydromethyltestosterone (oral turinabol). It is an orally active designer prohormone that converts partially in vivo toward a turinabol-like non-aromatising androgen, giving dry lean gains with 17-alpha-alkylated hepatotoxicity and no human trial data.

A very long-acting undecanoate ester of drostanolone (Masteron), a non-aromatising DHT-derived steroid. While the propionate and enanthate esters of drostanolone are common, the undecanoate would extend release to allow much less frequent injection. It has no pharmaceutical precedent and is a niche underground ester within the drostanolone family, offering Masteron's dry, hardening effect over a longer duration.

Formyltrienolone (RU-2341) is a highly potent trenbolone-family (estra-4,9,11-triene) synthetic steroid characterised chiefly in preclinical endocrine research. It is an extremely strong androgen-receptor and progesterone-receptor ligand from the same Roussel-Uclaf lineage as metribolone and trenbolone, with no clinical use and essentially no human data.

LGD-3303 is a non-steroidal SARM studied preclinically for muscle and bone, notably in osteoporosis models. It has no human data, so all information is preclinical or anecdotal. It shows good oral bioavailability in animals and is expected to share the class effects of testosterone suppression and lipid changes.

A hypothetical/underground injectable enanthate ester of mesterolone (Proviron), a 1-methyl DHT derivative normally taken orally without a 17-alpha-alkyl group. Esterifying mesterolone as an enanthate would allow a depot injection, converting an ordinarily weak, non-hepatotoxic oral androgen into a longer-acting injectable. It is essentially unstudied in this form and rarely encountered.

Methylstenbolone (M-Sten) is a potent 17α-methylated designer steroid, a methylated analogue of stenbolone. Reputed for strong dry mass and strength gains, it is highly hepatotoxic and strongly suppressive, with efficacy and safety data limited to anecdote and case reports.

An early synthetic anabolic steroid first investigated in the 1960s and later resurfacing as the first BALCO-era designer steroid identified in an athlete sample (2002). Some limited mid-century human data exist for growth applications; modern doping use is essentially uncharacterised.

Oxabolone cypionate (4-hydroxy-19-nortestosterone cypionate), an obscure injectable 19-nortestosterone derivative and a metabolite of the older steroid oxabolone. Marketed historically in a few European combination products, it is a mild nandrolone-family anabolic essentially uncharacterised in modern controlled studies.

S-23 is a potent non-steroidal SARM studied in animals partly as a candidate for male hormonal contraception because it strongly suppresses sperm production. Human data are absent. It is considered one of the more suppressive SARMs anecdotally, with the usual lipid and endocrine downsides and no established dosing.

Stenabolic (SR-9009) is not a SARM but a REV-ERB agonist studied in mice for effects on circadian metabolism, endurance and fat loss. It has essentially no human data and, critically, very poor oral bioavailability, casting doubt on whether oral use produces meaningful effects. It does not act on the androgen receptor, so no steroid profile applies.

A rare injectable derivative of dihydrotestosterone (2-methyl-1-dehydro-DHT) with an acetate ester, briefly marketed as Anatrofin. It is a moderately anabolic, non-aromatising DHT-class steroid conceptually similar to a boldenone-flavoured masteron, giving dry, lean effects. It saw little clinical use and has essentially no modern human data.

The propionate ester of stenbolone (2-methyl-DHB), a mild non-aromatising injectable DHT-derivative. Historically a rare veterinary/human anabolic; the propionate ester gives a short-acting depot. Dry, low-estrogen gains with modest potency.

Testolone enanthate is a purported esterified, injectable prodrug of the SARM testolone (RAD-140), sold on the grey market as a longer-acting alternative to oral RAD-140. It is distinct from the marketed RAD-150 (a benzoate ester also sold as "testolone ester"). There is essentially no published human pharmacology for an enanthate ester of RAD-140.

A very long-ester form of trenbolone using the undecanoate ester, giving the slowest release of the common trenbolone preparations. It offers the same extremely potent, non-aromatising trenbolone activity with far less frequent injection, at the cost of a very long time to clear and delayed offset of side effects. It has no clinical history and only anecdotal human data.

YK-11 is a synthetic steroidal compound often grouped with SARMs but structurally a steroid derived from DHT. Its main proposed action is inhibition of myostatin signalling via follistatin, based only on cell-culture work. There is no human data; all effects and risks are preclinical or anecdotal, and it carries steroid-like suppression and possible hepatotoxicity.

Trenavar (trendione, estra-4,9,11-triene-3,17-dione) is a non-methylated prohormone that converts to trenbolone. Reputed for dramatic dry recomposition, it also inherits trenbolone's harsh side-effect profile — night sweats, aggression, and cardiovascular strain — on anecdotal evidence only.

The dipropionate ester of bolandiol (19-nor-4-androstenediol / estr-4-ene-3β,17β-diol), an injectable 19-nor prohormone that converts toward nandrolone. Historically used in some European tonics; the diester provides a longer-acting depot. Carries the nandrolone-family profile.

An azine-linked dimer of methasterone (superdrol) sold as a "designer" oral supplement in the late 2000s. The azine bond cleaves in the body to release two active methasterone-like molecules. Linked in case reports to cholestatic liver injury.

Dymethazine (DMZ) is an azine-linked designer steroid — essentially two methasterone (superdrol) molecules joined by a nitrogen bridge — that splits into methasterone-like halves in the body. It offers strong dry gains anecdotally but shares superdrol's high hepatotoxicity and strong suppression.

GLPG0492 (DT-200) is a non-steroidal selective androgen receptor modulator developed by Galapagos, studied preclinically for muscle-wasting conditions such as cachexia and Duchenne muscular dystrophy. It showed muscle-sparing effects in animal models with limited prostate stimulation, but has not completed human efficacy trials in the public record.

A medium-acting caproate (hexanoate) ester of methenolone, sitting between the short acetate and long enanthate esters of the mild Primobolan parent. The caproate ester would give a release duration slightly shorter than enanthate, useful for smoothing blood levels of this gentle, non-aromatising DHT derivative. It has essentially no pharmaceutical history and is a niche underground ester.

Methoxygonadiene ('Max LMG', 13-ethyl-3-methoxy-gona-2,5(10)-dien-17-one) is an orally active 19-nor designer prohormone that acts largely as a progestin/prohormone toward dienolone-type 19-nor androgens. Sold to add 'wet' size and enhance stacked compounds, it is progestogenic, non-aromatising, and — being non-methylated at C17 — comparatively less hepatotoxic than typical designer orals, though still suppressive.

Methylhydroxynandrolone (MHN, 17alpha-methyl-4-hydroxy-19-nortestosterone) is an orally active designer steroid combining a 19-nor backbone with a 4-hydroxy group (the oxymetholone/oxabolone-type anti-estrogen motif) and 17-alpha-methylation. It offers dry, non-aromatising anabolic gains but is regarded as notably hepatotoxic even among methylated orals, with only anecdotal human data.

A 2,17α-dimethyl DHT-derived designer oral (2,17α-dimethyl-5α-androsta-1-en-17β-ol-3-one) that appeared in pro-hormone supplements alongside dymethazine. Non-aromatising and strongly hepatotoxic; implicated in a published case of cholestatic jaundice.

A stanozolol-related designer steroid sold widely in 'prohormone' supplements in the mid-2000s until regulators identified it. Structurally close to winstrol but lacking the C17 methyl group; human data are limited to anecdote and analytical seizures.

A 19-nor 'prohormone' (dienedione) sold as a trenbolone precursor, intended to convert toward dienolone/trenbolone-type metabolites. Popular in gray-market products until regulation; human data are limited to anecdote and conversion inference.

Methoxygonadiene (Max LMG) is a progestin-derived prohormone that converts toward the potent progestin/anabolic promagnon-type steroid. Used as a non-aromatising 'wet' bulking base with anti-estrogen synergy, its effects and its progestogenic risks are documented only anecdotally.

MK-4541 is an experimental compound from Merck characterised as a selective androgen receptor modulator with additional 5-alpha-reductase inhibitory activity, intended to give muscle-anabolic effects while limiting prostate stimulation. It is preclinical, with no human efficacy or safety data.

6-Bromoandrostenedione (6-bromo) is a brominated androstenedione derivative marketed as a suicidal aromatase inhibitor rather than an anabolic prohormone. Sold to raise testosterone by blocking estrogen synthesis, its human efficacy is essentially unstudied and rests on anecdote.

BMS-564929 is an experimental non-steroidal SARM from Bristol-Myers Squibb noted in preclinical work for very high anabolic potency and strong tissue selectivity for muscle over prostate. It is highly suppressive of the HPG axis in animal models and has no established human efficacy or safety data.

A 19-nortestosterone prohormone (estra-4-ene-3beta,17beta-diol) that converts to nandrolone in the body. Marketed in supplements before regulation; limited human data, mostly from doping analysis and prohormone-conversion studies.

LGD-2226 is an experimental non-steroidal SARM from Ligand Pharmaceuticals studied in rodents for anabolic effects on muscle and bone with reduced prostate stimulation. It predates the better-known LGD-4033 and has no human clinical data.

The acetate ester of norclostebol (4-chloro-19-nortestosterone), a 19-nor/chlorinated injectable androgen used historically in some European and veterinary products. A relative of clostebol and nandrolone; a recurring anti-doping finding, including via contamination.

An almost purely theoretical testosterone ester in which the 17-beta hydroxyl is esterified with formic acid, the shortest possible carboxylic acid. The one-carbon formate group provides essentially no depot lag, so it would behave almost like unesterified testosterone suspension with a very rapid, spiking release. It has no pharmaceutical history and appears only occasionally as a novelty in underground discussion.

An 11-oxygenated androgen (11-ketotestosterone / 11-oxo-testosterone) that is the principal androgen in fish and a natural minor human adrenal-pathway steroid. Marketed as a gray-market oral/prohormone; human anabolic data are minimal.

An extremely potent research androgen, 2,2-dimethyl analogue of metribolone (methyltrienolone), originally studied by Roussel-Uclaf as R2956. It was investigated as an antiandrogen research tool rather than a therapeutic and is far too toxic and suppressive for practical use. It appears occasionally as a designer steroid and on anti-doping lists; genuine human data are effectively nonexistent.

4-hydroxy-17α-methyl-δ1-testosterone, a 17α-alkylated oral AAS closely related to methandienone and oxymesterone that was synthesised but never marketed. Barely studied; the 4-hydroxy group suggests weak aromatisation and mild anti-estrogen character on paper.

Formyldienolone (2-formyl-17-methyl-17-hydroxyestra-2,4-dien-3-one type designer steroid) is an obscure orally-active methylated 19-nor androgen appearing in grey-market prohormone products. It has essentially no clinical characterisation; it is treated as a progestational, non-aromatising 17-alpha-alkylated nandrolone-type oral with expected hepatotoxicity and strong suppression.

A very obscure injectable anabolic steroid, an enol-ether derivative in the dihydrotestosterone/1-testosterone family that acts as a prodrug releasing an active DHT-type androgen. Studied only briefly in the mid-20th century, it never reached meaningful clinical use and has essentially no modern human data, appearing mainly in old steroid literature and anti-doping references.

S-40503 is an experimental selective androgen receptor modulator developed as a candidate for osteoporosis, characterised in rodents by a strong bone-anabolic effect with comparatively little effect on the prostate. It has no human clinical trials; all data are preclinical, and its presence in the grey-market 'research chemical' supply is driven by anecdote rather than evidence.

AC-262536 (AC-262,536) is an experimental non-steroidal SARM originally studied by Acadia Pharmaceuticals for benign prostatic hyperplasia and possible cognitive applications. It acts as a partial agonist at the androgen receptor with anabolic activity in animal models but has no human efficacy or safety data.

A grey-market androstadiene-dione prohormone (androsta-3,5-diene-7,17-dione-adjacent dione) marketed as a designer "pro-anabolic" that converts in vivo toward an active androgen. Essentially uncharacterised in humans; sold in supplements after the 2005 and 2014 prohormone crackdowns.

A 4-chloro, 17alpha-methylated designer steroid marketed briefly in gray-market products, combining the chlorinated backbone of clostebol with oral C17 alkylation. Essentially no human research; considered non-aromatising and orally hepatotoxic.

A potent 17alpha-methylated 19-nor designer steroid (a diene analogue of methyltrienolone/metribolone chemistry) marketed briefly in gray-market products. Highly potent in preclinical assays but essentially no human safety data and notable hepatotoxicity risk.

An obscure DHT-derived androgen (a nitrosocarbamate ester of a 5α-androstane) once explored as a potential androgen/contraceptive adjunct. Essentially uncharacterised in modern human use; catalogued here as a genuine but near-forgotten synthetic androgen.

AC-186 is a non-steroidal selective androgen receptor modulator studied preclinically for neuroprotective and anabolic effects, including in models of spinal cord injury and neuromuscular function. It has been characterised as tissue-selective in animals but has no published human trials.

A 19-nortestosterone-derived steroid with an added ring double bond, related to trenbolone and dienogest chemistry. Investigated briefly in mid-century animal work and later appearing as a prohormone target; virtually no human data.

LG-121071 is one of the earliest non-steroidal selective androgen receptor modulators, a quinolinone compound identified by Ligand Pharmaceuticals in the 1990s during the initial search for orally active tissue-selective androgens. It demonstrated anabolic activity in rodents but never advanced to human trials, and it is of largely historical and research interest.

RAD-150 (TLB-150) is a testosterone-ester-like derivative marketed as the 'benzoate ester' of the SARM RAD-140 (testolone). It is essentially uncharacterised: there are no controlled studies of RAD-150 itself, and grey-market claims rely on extrapolation from RAD-140 plus user anecdote.

A grey-market estra-4,9-diene prohormone class marketed as a precursor that converts toward trenbolone-like 19-nor androgens. Follows the trendione (trenavar) template. Human evidence is essentially nil; strongly progestogenic and suppressive if conversion occurs.

JNJ-28330835 is a non-steroidal selective androgen receptor modulator investigated by Johnson & Johnson in preclinical studies, notable for showing anabolic effects on muscle while acting as an antagonist or weak agonist in the prostate. It has no published human data and is essentially a research tool compound.

An obscure 11β-hydroxy C19 steroid (11β-hydroxyandrostenedione-type) assigned an anabolic-steroid INN but essentially never characterised in humans. Related 11β-hydroxy androgens have very weak direct anabolic/androgenic activity but serve as precursors to potent 11-oxygenated androgens.